Uses / Indications

Artesunate injection is an antimalarial medicine used for the treatment of severe malaria, particularly malaria caused by Plasmodium falciparum, in accordance with applicable product authorisation and clinical guidelines.

Its use may include:

• Severe falciparum malaria: Injectable artesunate is an established treatment for severe malaria in eligible adults and children.

• Patients requiring parenteral treatment: Used when the severity of malaria or the patient’s clinical condition requires treatment by an injectable route.

• Transition to oral antimalarial therapy: Treatment with injectable artesunate should be followed by a complete course of an appropriate oral antimalarial combination regimen, as directed by current clinical guidance.

The precise indication and eligible patient population must be checked against the approved information for the product and the relevant national treatment guidelines. Injectable artesunate should not be assumed to prevent all malaria relapses.

6. Benefits

• Contains artesunate, an established antimalarial active ingredient.

• Available in the stated 30 mg, 60 mg and 120 mg strength presentations, subject to supplier confirmation.

• Provides a dry powder presentation for preparation according to approved product instructions.

• Supports treatment of severe malaria when administered by qualified healthcare professionals.

• May be considered for pharmaceutical sourcing and export enquiries, subject to verified availability and destination-market requirements.

These are general product characteristics, not guarantees of treatment success or claims of superiority over other antimalarial medicines.

7. Side Effects

Common Side Effects

Reported adverse effects associated with injectable artesunate may include:

• Nausea or vomiting.

• Dizziness or headache.

• Gastrointestinal symptoms.

• Injection-related reactions, depending on the formulation and administration method.

Some symptoms may also arise from malaria itself. The actual adverse-effect profile depends on the product and clinical circumstances.

Less Common or Serious Side Effects

Important risks include:

• Delayed haemolytic anaemia: Destruction of red blood cells can occur after treatment, requiring appropriate follow-up.

• Hypersensitivity reactions: Serious allergic reactions may occur.

• Other clinically significant blood abnormalities: These may require assessment and monitoring according to the product information.

• Other serious reactions: These should be evaluated in the context of the patient’s condition and the approved prescribing information.

Patients treated for severe malaria may require clinical and laboratory follow-up after treatment, including assessment for delayed haemolysis when indicated. Suspected serious adverse reactions require prompt medical evaluation.

8. How Does It Work?

Artesunate is an artemisinin derivative with antimalarial activity. It is converted in the body to dihydroartemisinin, an active metabolite. Artemisinin derivatives act against susceptible malaria parasites through mechanisms involving reactive intermediates and damage to parasite proteins and other cellular components.

This activity helps reduce the parasite burden in the blood. Artesunate is an antimalarial, not a cephalosporin or a general-purpose antibacterial medicine.

9. Dosage Guidelines

The dose and treatment regimen must be determined by a qualified healthcare professional according to the patient’s condition and the approved product information.

Relevant factors include:

• Patient body weight and age.

• Severity of malaria.

• Clinical response and ability to take oral medication.

• The prescribed route of administration.

• The specific product strength and its approved preparation instructions.

• Applicable national or international malaria treatment guidance.

Do not treat the vial strength as the patient’s prescribed dose. Although established artesunate regimens for severe malaria are weight-based, the exact dose, timing, route, preparation method and transition to oral therapy must follow the applicable clinical guidelines and approved product instructions.

Do not assume that reconstitution volumes, diluents, final concentrations or administration techniques are identical across the 30 mg, 60 mg and 120 mg presentations.

Injectable artesunate requires professional preparation and administration. It must not be used for self-medication.

10. When Not to Use

The product should not be used in patients with a known serious hypersensitivity to artesunate or relevant product components, as specified in the approved prescribing information.

Before treatment, the healthcare professional should assess:

• Known allergies or previous serious reactions to artesunate.

• The patient’s clinical condition and other relevant medical history.

• Pregnancy or breastfeeding, where applicable.

• Potential interactions with other medicines.

• Any product-specific contraindications or restrictions.

Severe malaria is a medical emergency. Treatment decisions must not be delayed while attempting self-treatment or seeking an unverified product. The exact contraindications should be confirmed from the approved information for the supplied formulation.

11. Drug / Product Interactions

Potential interaction considerations depend on the patient’s full treatment regimen and the specific product information.

• Other antimalarial medicines: Selection of follow-on oral therapy must follow applicable malaria treatment guidance.

• Medicines affecting blood parameters: Consider the patient’s clinical history and any medicines that may complicate the assessment of anaemia or other blood abnormalities.

• Other prescription medicines: The treating clinician should review the full medication list and assess clinically relevant interactions.

Do not assume that different antimalarial medicines can be combined interchangeably. Do not mix artesunate with another injectable medicine or infusion solution unless the exact product documentation confirms compatibility.

12. Safety Advice

• Use only under the supervision of appropriately qualified healthcare professionals.

• Confirm the product name, strength, batch number and expiry date before preparation.

• Inspect the vial and packaging for damage or compromised integrity.

• Follow the approved product-specific preparation and administration instructions.

• Assess for known allergies before treatment.

• Monitor the patient according to the severity of malaria and the prescribed treatment plan.

• Arrange appropriate follow-up for delayed haemolysis and other clinically relevant complications.

• Ensure that treatment is followed by a complete course of appropriate oral antimalarial therapy when directed by the applicable guidelines.

• Do not use the medicine for self-medication.

• Report suspected serious adverse reactions promptly.

13. General Instructions

• Verify the strength and presentation against the product label.

• Read the approved package insert before preparation.

• Use appropriate aseptic procedures.

• Use only the specified diluent and preparation method.

• Follow the authorised route and administration instructions.

• Do not assume that the same preparation method applies to all manufacturers or vial strengths.

• Inspect the prepared solution according to the manufacturer’s acceptance criteria.

• Do not use a preparation that fails the specified criteria.

• Do not assume compatibility with other medicines or infusion fluids.

• Follow the approved instructions for use after preparation.

• Dispose of unused medicine and preparation materials according to applicable procedures.

The availability of separate solvent or diluent ampoules must be confirmed for the exact product. WHO-listed artesunate presentations differ in their supplied components and packaging.

14. Special Dietary / Lifestyle Tips

There is no universal dietary regimen specific to artesunate injection. During recovery from malaria, patients should:

• Follow the prescribed treatment and follow-up schedule.

• Maintain appropriate fluid intake as advised by the treating healthcare professional.

• Report worsening symptoms or new symptoms promptly.

• Attend recommended follow-up assessments, including blood tests where indicated.

• Complete the prescribed follow-on oral antimalarial regimen.

Patients should not stop treatment, alter the regimen or use additional antimalarial medicines without professional advice. Dietary measures cannot replace appropriate antimalarial treatment.

15. Comparison with Other Treatments

Artesunate injection is not interchangeable with oral antimalarial medicines solely because they share the same therapeutic purpose. The choice and sequence of treatment depend on disease severity, clinical response, patient factors and applicable treatment guidelines.

16. Precautions & Warnings

• Severe malaria: Requires urgent medical management and appropriate monitoring.

• Delayed haemolysis: Follow-up may be necessary after treatment to identify delayed red-cell destruction.

• Hypersensitivity: Review the patient’s allergy history and monitor for serious reactions.

• Preparation requirements: Use only the product-specific approved preparation instructions.

• Pregnancy and breastfeeding: Follow current clinical guidance and the approved product information.

• Patient monitoring: Assess clinical response and other relevant laboratory parameters as indicated.

• Treatment completion: Ensure appropriate follow-on oral antimalarial treatment under the applicable guidelines.

• Product verification: Confirm that the supplied strength, diluent components and documentation match the intended presentation.

Do not assume that every precaution or preparation instruction is identical across artesunate injection products.

17. Can I Use It With Other Medicines or Antibiotics?

Artesunate may form part of a wider treatment plan, but concomitant medicines must be selected by a qualified healthcare professional.

• Inform the healthcare team about all current medicines and supplements.

• Follow the prescribed oral antimalarial regimen after injectable treatment when directed.

• Do not add antibiotics unless there is a separate clinical indication.

• Do not combine or substitute antimalarial medicines without professional guidance.

• Do not mix artesunate with another injectable medicine in the same syringe, vial or infusion container without documented compatibility.

Clinical drug interactions and physical compatibility during preparation are separate matters and require appropriate verification.

18. Storage

Store according to the manufacturer’s approved product labelling. Refer to the product packaging or package insert for the applicable storage conditions.

Do not assume that storage temperature, protection from light, shelf life or stability after preparation is the same for every presentation. Confirm whether the supplied product includes separate solvent or diluent components and follow the storage instructions for the complete pack.

19. Frequently Asked Questions (FAQs)

1. What is Artesunate Injection 30mg/60mg/120 Mg used for?

Injectable artesunate is an antimalarial medicine used to treat severe malaria according to approved prescribing information and applicable treatment guidelines.

2. What is the active ingredient?

The active ingredient is artesunate.

3. Which strengths are listed?

The supplied product name lists 30mg, 60mg and 120 Mg. Availability of each strength should be confirmed with the supplier.

4. Is artesunate an antibiotic?

No. Artesunate is an antimalarial medicine, not a cephalosporin or a conventional antibacterial antibiotic.

5. Which route of administration is used?

The authorised route depends on the specific product. Certain approved presentations permit intravenous or intramuscular administration, while others specify intravenous use only. Confirm the route from the exact product information.

6. How should the powder be prepared?

Follow the approved product-specific instructions for the exact strength. The diluent, preparation method and administration requirements must be verified before use.

7. Does artesunate injection require follow-up after treatment?

Yes. Follow-up may be required to monitor recovery and detect delayed haemolysis or other complications. Follow the treating healthcare professional’s monitoring plan.

8. Is artesunate injection available for pharmaceutical export?

Kelar Pharmachem India supports pharmaceutical sourcing and export enquiries. Product availability, supplier documentation, destination-market requirements and the exact vial presentation must be confirmed before an order is placed.